Concerns over cannabis drug product cost
National Centre for Pharmaco-Economics finds Sativex is not cost-effective
Makers of MS drug reapply to be covered by HSE scheme
Patients are currently paying €500 a month for Fampridine
MS patients to pay up to €400 for ‘crucial’ drug
Fampyra had been provided free for 2½ years under clinical trial by manufacturer Biogen
Biogen to reapply for HSE funding for multiple sclerosis drug
Authorities said in 2012 Fampyra not demonstrably cost-effective for treatment of MS
Medicines board says it has ‘no immediate issues’ with blood thinners despite reactions
Director of the National Centre for Pharmaco-economics says he has ‘real concerns’ about new generation of anti-coagulants
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Stardust
Inquests into the nightclub fire that led to the deaths of 48 people
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices